Daito Pharmaceutical Co.,Ltd.
4577・Prime Market・Pharmaceuticals
Governance
Company with an Audit and Supervisory Committee. The Board of Directors consists of 9 members in total: 5 directors who are not members of the Audit and Supervisory Committee and 4 Audit and Supervisory Committee members (including 4 outside directors). A Nomination and Compensation Advisory Committee has been established as an advisory body to the Board of Directors, chaired by an independent outside director. The company has adopted an executive officer system and management committee to separate decision-making from business execution.
Risk Management
The company has established a Crisis Management Committee (chaired by the Representative Director and President) based on its Crisis Management Regulations, and identifies risk factors in each department through enhanced internal audits. Material risks are deliberated by the Board of Directors and addressed promptly. Risk reduction is pursued through distribution of a Compliance Handbook, an internal whistleblowing system, and collaboration with retained legal counsel. Sustainability risks are identified and assessed by a working group, deliberated at management meetings, and approved by the Board of Directors.
Shareholder Returns
Annual dividend for FY2026 (ending May 2026) is ¥40 per share (interim ¥20 + year-end ¥20), with a payout ratio of 37.2%. The forecast for FY2027 (ending May 2027) is ¥45 (interim ¥22.50 + year-end ¥22.50). The company also conducted share buybacks (total 1,242,000 shares, ¥1,631 million) and cancellations (1,242,000 shares, ¥1,626 million).
Dividend Policy
Under the medium-term management plan DTP2027, the company's policy is progressive dividends, paid twice a year (interim and year-end). Actual results for FY2026 (ending May 2026) were an annual dividend of ¥40 per share (interim ¥20 + year-end ¥20), with a payout ratio of 37.2% and a net asset dividend ratio (DOE) of 2.2%. The forecast for FY2027 (ending May 2027) is an annual dividend of ¥45 (interim ¥22.50 + year-end ¥22.50), with a projected payout ratio of 43.1%. Note that a 2-for-1 stock split was implemented effective June 1, 2025, and the annual dividend of ¥70 for FY2025 (ending May 2025) (interim ¥35 + year-end ¥35) is shown as the actual pre-split amount.
ESG
As part of climate change response, the company conducted scenario analysis (1.5°C and 4°C) in line with TCFD recommendations, and has set targets of a 25% reduction in Scope 1+2 emissions by FY2030 (versus base year) and net-zero emissions by FY2050. In FY2025 (ending May 2025), GHG emissions were Scope 1: 9,169 t-CO2, Scope 2: 19,741 t-CO2, and Scope 3: 99,978 t-CO2. In terms of human capital, the company has positioned "investment in human capital" as a pillar of its medium-term management plan, implementing tiered training programs, e-learning, an internal job posting system, and progressive wage increases. The ratio of female managers stands at 10.0%, the male childcare leave utilization rate at 55.5%, and the employment rate of persons with disabilities at 1.9% (below the statutory requirement of 2.5%).
Last updated: August 27, 2025